Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
15.26 EUR | +1.60% |
|
-4.51% | -8.18% |
Feb. 10 | Medincell: a milestone payment from Teva | CF |
Feb. 10 | Medincell: a milestone payment from Teva | CF |
Company Valuation: MedinCell S.A.
Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 119.8 | 287.6 | 186.4 | 246.2 | 275.7 | 439 | - | - |
Change | - | 140.1% | -35.19% | 32.11% | 11.97% | 59.24% | - | - |
Enterprise Value (EV) 1 | 119.8 | 287.6 | 209.3 | 294.4 | 318.1 | 487.1 | 475.7 | 449.3 |
Change | - | 140.1% | -27.23% | 40.69% | 8.03% | 53.14% | -2.33% | -5.55% |
P/E ratio | -5.01x | -13.6x | -7.42x | -7.72x | -10.9x | -23.1x | 35.8x | 9.82x |
PBR | - | - | -13.9x | -5.86x | -6.68x | -8.84x | 300x | - |
PEG | - | 0.5x | -0.5x | -0.3x | 0.4x | 0.9x | -0x | 0x |
Capitalization / Revenue | 42x | 35.1x | 45.6x | 24.9x | 30.5x | 20.2x | 11.2x | 5.06x |
EV / Revenue | 42x | 35.1x | 51.2x | 29.8x | 35.2x | 22.4x | 12.1x | 5.18x |
EV / EBITDA | - | - | -9.39x | -13.2x | -16.5x | -40.9x | 70x | 8.93x |
EV / EBIT | -6.2x | -18.7x | -8.79x | -12.3x | -15.2x | -63.2x | 31.9x | 9.08x |
EV / FCF | - | - | -9.1x | -13.4x | -24.3x | -122x | 94.5x | 11.7x |
FCF Yield | - | - | -11% | -7.48% | -4.12% | -0.82% | 1.06% | 8.52% |
Dividend per Share 2 | - | - | - | - | - | - | - | - |
Rate of return | - | - | - | - | - | - | - | - |
EPS 2 | -1.19 | -0.86 | -1 | -1.27 | -0.88 | -0.65 | 0.42 | 1.53 |
Distribution rate | - | - | - | - | - | - | - | - |
Net sales 1 | 2.852 | 8.186 | 4.091 | 9.889 | 9.032 | 21.71 | 39.26 | 86.75 |
EBITDA 1 | - | - | -22.3 | -22.36 | -19.26 | -11.9 | 6.8 | 50.3 |
EBIT 1 | -19.32 | -15.37 | -23.81 | -24.02 | -20.94 | -7.706 | 14.9 | 49.5 |
Net income 1 | -23.92 | -19.02 | -24.81 | -29.5 | -25.04 | -16.09 | 9.967 | 44.7 |
Net Debt 1 | - | - | 22.87 | 48.18 | 42.34 | 48.05 | 36.7 | 10.3 |
Reference price 2 | 5.96 | 11.70 | 7.42 | 9.81 | 9.59 | 15.02 | 15.02 | 15.02 |
Nbr of stocks (in thousands) | 20,097 | 24,581 | 25,121 | 25,101 | 28,749 | 29,229 | - | - |
Announcement Date | 6/4/20 | 6/16/21 | 6/14/22 | 6/26/23 | 6/10/24 | - | - | - |
P/E ratio, Detailed evolution
P/E ratio (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Yield (Y) | Capi.($) | ||
---|---|---|---|---|---|---|
-23.11x | 22.44x | -40.93x | -.--% | 453M | ||
70.58x | 17.84x | 49.86x | 0.6% | 782B | ||
22.44x | 7.93x | 15.45x | 2.25% | 378B | ||
22.27x | 4.31x | 12.58x | 3.09% | 371B | ||
43.21x | 7.05x | 16.25x | 3.27% | 336B | ||
15.4x | 3.76x | 9.3x | 3.42% | 256B | ||
27.23x | 4.64x | 14.65x | 2.14% | 225B | ||
16.62x | 4.18x | 10.11x | 3.57% | 210B | ||
32.28x | 6.26x | 11x | 3.06% | 158B | ||
15.2x | 3.25x | 8.19x | 6.44% | 147B | ||
Average | 24.21x | 8.17x | 10.65x | percentage-no-prefix | 286.48B | |
Weighted average by Cap. | 37.49x | 8.83x | 22.94x | percentage-no-prefix |
Year-on-year evolution of the PER
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- MEDCL Stock
- Valuation MedinCell S.A.